Literature DB >> 22187239

Comparison of efficacy of enucleation and pancreaticoduodenectomy for small (<3 cm) branch duct type intraductal papillary mucinous neoplasm located at the head of pancreas and the uncinate process.

Ho Kyoung Hwang1, Joon Seong Park, Jae Keun Kim, Chang-Min Park, Shin Il Cho, Dong Sup Yoon.   

Abstract

PURPOSE: Accurate indications and the extent of surgery for branch duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas are still debatable. In particular, small tumor is located at the head portion of pancreas presents a dilemma. The purpose of this study is to compare the efficacy of enucleation (EN) with that of pancreaticoduodenectomy (PD) in patients with small (2 cm<size<3 cm) branch duct IPMN located at the head of pancreas or uncinate process.
MATERIALS AND METHODS: Among 155 patients who underwent pancreatic surgery due to pancreatic cystic tumors between January 2000 and December 2007 at Yonsei University Health System in Seoul, Korea, 14 patients with small (2 cm<size<3 cm) branch duct IPMN located at the head of pancreas or uncinate process were included in this study. Ten patients underwent PD, and four patients underwent EN. We compared short term surgical outcomes between the two groups. Correlation of the variables was analyzed using Mann-Whitney test and Fisher's exact test (SPSS Window 12.0). p-values less than 0.05 were considered significant.
RESULTS: The average age was 62.21 years (±6.71 years) and consisted of 8 men and 6 women. The mean operation time and blood loss were significantly lower in EN group. There were no significant differences in other surgical morbidities.
CONCLUSION: The result suggests that enucleation for small branch duct IPMN located at the head of pancreas or uncinate process is feasible and as safe as PD, despite a high rate of minor complications.

Entities:  

Mesh:

Year:  2012        PMID: 22187239      PMCID: PMC3250335          DOI: 10.3349/ymj.2012.53.1.106

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


INTRODUCTION

Thanks to the development of diagnostic tools, intraductal papillary mucinous neoplasm (IPMN) of the pancreas has increasingly been detected in asymptomatic patients.1-3 A branch duct IPMN smaller than 3 cm should sometimes be considered as an indication for surgical resection, even though it is associated with a lower risk of malignancy.4 Since the malignant risk of small branch duct IPMNs is uncertain, it is difficult for surgeons to determine the treatment modality, especially if the lesion is located at the head of pancreas or uncinate process. Possible surgical modalities for a branch duct IPMN at the pancreatic head include pancreaticoduodenectomy (PD), pylorus preserving PD (PPPD), duodenum preserving pancreatic head resection, and enucleation. PD is recommended whenever there is a doubt for the presence of malignant risks. However, it is difficult to accurately diagnose the presence of carcinoma in situ or invasive carcinoma for IPMN on preoperative imaging study. Thus, indications and extent of surgery for branch duct IPMN of the pancreas are still debatable. For branch duct IPMNs with a borderline risk of malignancy, a limited resection (duodenum preserving pancreatic head resection or enucleation) can be applied with less invasiveness. However, duodenum preserving pancreatic head resection is technically more demanding than PD. Numerous studies have examined the feasibility of surgical resection of a small branch duct IPMN, however, most of them have focused only on organ preserving pancreatic resection.5-7 We, therefore, compared the efficacy of enucleation with that of PD in patients with small (2 cmpancreas and uncinate process.

MATERIALS AND METHODS

Patients

This study, including the retrospective chart review and data collection, was approved by the Institutional Review Board of Yonsei University. We retrospectively reviewed 155 patients who underwent pancreatic surgery for cystic lesions in the pancreas between January 2000 and December 2007 at the Department of Surgery, Yonsei University College of Medicine. Among these patients, 14 patients who had branch duct type IPMN at the pancreatic head and uncinate portion with sizes between 2 cm and 3 cm were selected for the study. Among them, 10 patients underwent PD or PPPD, and 4 underwent enucleation. In the enucleation group (EN group), the tumor was located away from the main pancreatic duct, not abutting to the main pancreatic duct and there was no mural nodule on imaging studies. We did not routinely perform Endoscopic Ultrasonography Fine Needle Aspiration. We determined surgery and the type of surgery according to tumor size, presence of mural nodule, and distance between tumor and main pancreatic duct (not abutting to the main pancreatic duct). Pathologic diagnoses were provided by an expert pathologist and all patients were closely followed until December 2008. All patients were followed up for more than 12 months, and the mean duration of follow up was 53.57 months (range: 12 to 129). The patients were divided into two groups according to the type of surgery: PD group and EN group. The two groups were compared in terms of age, gender, size of tumor, pathology, short term surgical outcomes such as operation time, blood loss, length of hospital stay, complications, operative mortality, and tumor recurrence.

Statistical analysis

Correlation of the variables was analyzed using Mann-Whitney test and Fisher's exact test (SPSS Window 12.0). p-values less than 0.05 were considered significant.

RESULTS

Patients characteristics

This study included 8 male and 6 female patients. Their average age was 62.21 years (±6.71 years). There was no significant difference in age, gender, size of tumor and pathology between the two groups (Table 1). However, tumor size was significantly larger in the EN group than the PD group.
Table 1

Patient Characteristics according to Type of Operation on Small Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreatic Head Portion

PD, pancreaticoduodenectomy; EN, enucleation.

The mean operation time and intraoperative blood loss were significantly less in the EN group than the PD group. Both the length of hospital stay and time to normal intake of soft diet were shorter in the EN group, but there was no statistical significance (Table 2).
Table 2

Surgical Outcomes according to Type of Operation on Small Branch Duct Intraductal Papillary Mucinous Neoplasms of Pancreatic Head Portion

PD, pancreaticoduodenectomy; EN, enucleation

Postoperative complications occurred in 2 of 4 patients in the EN group, acute pancreatitis in 1 patient (amylasemia, no clinical symptoms) and delayed gastric emptying in 1 patient (Table 3). There was no operative mortality in either groups.
Table 3

Morbidity and Mortality according to Type of Operation on Small Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreatic Head Portion

PD, pancreaticoduodenectomy; EN, enucleation; DGE, delayed gastric emptying.

The average follow up period was 43.25 months (range: 12 to 112) in the EN group, and 57.70 months (range: 13 to 129) in the PD group. In the latter group, a single case with borderline IPMN lesions recurred in the remnant pancreas 96 months after PD. The patient refused surgery, and we decided to observe the lesions.

DISCUSSION

Pancreatic cystic lesions are increasingly identified due to several factors, including better quality of diagnostic tools, increasing routine physical check-ups, and increasing life span. Many studies correlating size and malignancy risk have revealed that small branch duct IPMNs are less likely to be malignant. A recent consensus conference recommended follow up every 3-6 months for lesions larger than 20 mm.8 However, based on results of a large-scale study on branch duct IPMNs in Korea,9 our institutional policy has been changed to perform surgical exploration for patients with lesions ≥2 cm in diameter. In this study, 1 patient (7.1%) had malignant lesions, which is in accordance with the results of other series that reported malignancy rates ranging between 6-46% in small branch duct IPMNs.8,9 Numerous factors are involved in deciding between surgical treatment or observation with routine radiologic check up for the management of small branch duct IPMN, such as the presence of mural nodule, tumor size, tumor location, age-specific life expectancy for benign cysts, and type of surgery. If the branch duct IPMN is located at the body or tail of the pancreas, there should be no hesitation in selecting a left side pancreatectomy with relatively low rate of morbidity than PD. A dilemma in selecting treatment modality arises if small branch IPMN lesions smaller than 3 cm are located at the head or uncinate process of pancreas. The natural course of small branch duct IPMN over time has not been well evaluated. Therefore, many surgeons have argued over an aggressive approach to the surgical management of pancreatic IPMNs. Recently, clinicians have recommended a more conservative approach.10 However, the malignancy potential of such lesions has been reported to range from 6% to 46%,11-19 which is much higher than the surgical mortality of PD in large volume centers.20-23 Therefore, we think that surgical resection is necessary for branch IPMN even if they are small in size and without clinical symptoms. There are many operative procedures for the management of small branch duct IPMNs located at the pancreatic head. Possible surgical modalities include PD, PPPD, duodenum preserving pancreatic head resection, and enucleation. For branch duct IPMN with low risk of malignancy, limited resection such as duodenum preserving pancreatic head resection and enucleation can be applied with less invasiveness and organ preservation. However, duodenum preserving pancreatic head resection is technically more demanding than PD. Compared to major pancreas resection surgery, enucleation is advantageous in that it entails lower surgical mortality, lower morbidity and complication rates, shorter hospital stay, and earlier return to normal daily activity.24-28 However, enucleation has two major drawbacks: recurrence rate and injury of the main pancreatic duct. To avoid the injury of the main pancreatic duct, we inserted an endoscopic pancreatic stent before operation. There was no early endoscopic procedure-related complications except pancreatitis. From an oncological point of view, complete frozen section biopsy of surgical margins is recommended for adequate surgical management.29 IPMNs should be re-resected if the operative margins are positive for malignancy. However, treatment for patients with margins positive for benign IPMN is controversial. In this study, only one case of recurrence was observed in the PN group. Because this recurrence occurred after definitive resection (R0 resection), one might assume that the transformation developed in the remnant pancreas. Misdiagnosis of an underlying IPMN could provide another explanation. The risk of developing a metachronous IPMN in a remnant pancreas is poorly elucidated. Nevertheless, we believe that this potential does not justify recommending total pancreatectomy for IPMN. This study suggests that enucleation could be a safe and effective tool for surgical extirpation. Small branch duct IPMN of the pancreatic head using intra-operative frozen section biopsy to rule out a small foci of malignancy will permit enucleation as a acceptable mode of therapy. In conclusion, it is controversial whether surgical treatment is needed for small branch duct IPMNs. However, there are some reasonable grounds for operation. It is not easy to preoperatively confirm a diagnosis and malignant potential of cystic tumors of the pancreas, and frequent follow up required for unconfirmed cystic lesions is socially-economically expensive. Moreover, there is a time dependent risk of malignant or invasive carcinoma throughout the adenoma-carcinoma sequence. This study suggests that enucleation for small (2 cmpancreatic head portion in asymptomatic patients could be feasible, and as safe as PD, despite a high rate of minor complications. The procedure may yield accurate diagnosis in uncertain cases preoperatively and the ability to treat the disease when management is still possible before progression to invasive carcinoma. Since this study included a very limited number of enucleation cases, more experience and long term surveillance for enucleation group should be followed.
  29 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Pancreatic cysts 3 cm or smaller: how aggressive should treatment be?

Authors:  Dushyant V Sahani; Anuradha Saokar; Peter F Hahn; William R Brugge; Carlos Fernandez-Del Castillo
Journal:  Radiology       Date:  2006-01-26       Impact factor: 11.105

3.  Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association.

Authors:  J Le Borgne; L de Calan; C Partensky
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

4.  Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management.

Authors:  M Kobari; S Egawa; K Shibuya; H Shimamura; M Sunamura; K Takeda; S Matsuno; T Furukawa
Journal:  Arch Surg       Date:  1999-10

5.  Intraductal papillary mucinous neoplasm of the pancreas: diagnosis and treatment.

Authors:  Masao Tanaka
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

6.  Long-term follow up results of intraductal papillary mucinous tumors of pancreas.

Authors:  Sun-Young Lee; Kyu Taek Lee; Jong Kyun Lee; Yong Hwan Jeon; Dongil Choi; Jae Hoon Lim; Jin Seok Heo; Seong Ho Choi; Kee-Taek Jang; Seung Woon Paik; Jong Chul Rhee
Journal:  J Gastroenterol Hepatol       Date:  2005-09       Impact factor: 4.029

7.  Intraductal papillary mucinous tumors of the pancreas: imaging studies and treatment strategies.

Authors:  M Sugiyama; Y Atomi
Journal:  Ann Surg       Date:  1998-11       Impact factor: 12.969

8.  Mucin-hypersecreting tumors of the pancreas: assessing the grade of malignancy preoperatively.

Authors:  K Yamaguchi; Y Ogawa; K Chijiiwa; M Tanaka
Journal:  Am J Surg       Date:  1996-04       Impact factor: 2.565

9.  Cystadenomas of the pancreas: is enucleation an adequate operation?

Authors:  M A Talamini; R Moesinger; C J Yeo; B Poulose; R H Hruban; J L Cameron; H A Pitt
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

10.  Risk of malignancy in resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report.

Authors:  C J Lee; J Scheiman; M A Anderson; O J Hines; H A Reber; J Farrell; M L Kochman; P J Foley; J Drebin; Y S Oh; G Ginsberg; N Ahmad; N B Merchant; J Isbell; A A Parikh; J B Stokes; T Bauer; R B Adams; D M Simeone
Journal:  J Gastrointest Surg       Date:  2007-11-27       Impact factor: 3.452

View more
  4 in total

Review 1.  Surgical Management of Pancreatic Cysts: A Shifting Paradigm Toward Selective Resection.

Authors:  Jon M Gerry; George A Poultsides
Journal:  Dig Dis Sci       Date:  2017-04-18       Impact factor: 3.199

Review 2.  Laparoscopic pancreatic resections.

Authors:  Dirk Bausch; Tobias Keck
Journal:  Langenbecks Arch Surg       Date:  2013-09-05       Impact factor: 3.445

Review 3.  [Minimally invasive pancreatic tumor surgery : oncological safety and surgical feasibility].

Authors:  D Bausch; T Keck
Journal:  Chirurg       Date:  2014-08       Impact factor: 0.955

4.  Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms.

Authors:  Timothy L Frankel; Jennifer LaFemina; Zubin M Bamboat; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; T Peter Kingham; William R Jarnagin; Peter J Allen
Journal:  HPB (Oxford)       Date:  2013-06-19       Impact factor: 3.647

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.